Breaking News

Selexis, Teneobio Enter Second Services Agreement

Will utilize Selexis’ SUREtechnology Platform to develop research cell banks for three additional preclinical candidates

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Selexis SA and Teneobio, Inc. have entered into a second services agreement to expand Teneobio’s oncology pipeline of Human Heavy-Chain Antibodies (UniAbs), a new class of multi-specific biologics. Teneobio will utilize Selexis’ SUREtechnology Platform to develop research cell banks (RCBs) for three additional preclinical candidates for the potential treatments of B-cell malignancies and prostate cancer. The companies entered their first services agreementin June 2017 to develop RCBs for multi-s...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters